Veradermics’ loss edges up to $21 million and G&A spending jumps (NYSE: MANE)

What happened

Veradermics, Incorporated (NYSE: MANE) reported a third-quarter net loss of $21.0 million, up $0.9 million from $20.1 million a year earlier.

Operating costs rose sharply, but $7.8 million of other income absorbed most of the increase. That included $5.1 million of interest income. Other income was $0.2 million in the third quarter of 2025.

Cash, cash equivalents and marketable securities stood at $798.4 million on Sept. 30, up $656.5 million from $141.9 million at Dec. 31, 2025. The company expects the balance to fund operations into 2030, through multiple Phase 3 readouts and a possible launch of its lead drug candidate, VDPHL01.

Key numbers

Metric	Latest	Change	Source
Net loss, Q3 2026	$21.0 million	from $20.1 million, +4.5%	Calculated from SEC 8-K
Cash, cash equivalents and marketable securities (vs. Dec. 31, 2025)	$798.4 million	from $141.9 million, +$656.5 million	Calculated from SEC 8-K
General and administrative expenses, Q3 2026	$12.7 million	from $2.3 million, +$10.5 million	SEC 8-K Exhibit 99.1
Research and development expenses, Q3 2026	$16.1 million	from $18.1 million, -$2.0 million	SEC 8-K Exhibit 99.1
Loss from operations, Q3 2026	$28.8 million	from $20.3 million, +$8.4 million	Calculated from SEC 8-K
Net loss, nine months ended Sept. 30	$71.7 million	from $48.1 million, +49.0%	Calculated from SEC 8-K

Read more: Veradermics (MANE) company research

Where the spending went

The operating loss widened to $28.8 million from $20.3 million in the third quarter of 2025, a gap of $8.4 million. General and administrative costs drove the change.

General and administrative expenses were $12.7 million, against $2.3 million a year earlier. The company says the $10.5 million increase came mainly from payroll and personnel costs. These include $3.1 million more in stock-based compensation, plus commercial readiness costs and other professional fees.

Research and development expenses moved the other way. They fell $2.0 million to $16.1 million from $18.1 million, mainly on lower clinical development and other development costs for VDPHL01. Higher payroll costs, including $0.8 million more in stock-based compensation, partly offset the decline.

Over nine months the pattern is the same on a larger scale. Net loss was $71.7 million, up 49.0% from $48.1 million a year earlier, by OptimistFi's calculation. General and administrative expenses reached $32.6 million, against $5.5 million. Research and development rose to $55.6 million from $43.9 million.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

The clinical data behind the quarter

Two registration-directed trials in men, Studies 302 and 304, together enrolled more than 1,000 male participants. In October, Veradermics said Phase 3 Study 304 met all primary and secondary endpoints with high statistical significance.

At Month 6 of Study 304, 68.7% of participants on twice-daily VDPHL01 and 55.7% on once-daily dosing reported improved or much improved hair coverage. The measure was the Androgenetic Alopecia Impact Rating Scale. In November, 12-month data from Study 302 showed 68.0% and 48.4% in the continued-treatment group on the same measure.

The company reports no treatment-related serious adverse events and no cardiac adverse events of special interest in either study. In women, the open-label Phase 2 Study 207 reported positive results in July. Enrollment in Study 306 was completed in August.

Why it matters

OptimistFi has argued that Veradermics is a high-burn bet. Its value depends on proving its therapy and financing it to approval without crippling dilution. This filing gives each half of that argument something to work with.

On proof, a Phase 3 trial met its endpoints and 12-month data held up. That supports the drug's case in men. On financing, a cash balance the company expects to last into 2030 eases the near-term need to raise money.

Quarterly net loss was almost unchanged. Spending beneath it is shifting toward administration and commercial readiness, and interest income on the larger cash pile is cushioning the result.

The caveat is the company's own. It lists a limited operating history, no products approved for sale, losses it expects to continue and a need for more financing. It also says its success depends on VDPHL01 winning approval. The 2030 runway is a forward-looking statement, and the 49.0% rise in nine-month net loss shows the burn is growing.

What's next

The company expects topline data from Phase 2/3 Study 306 in female pattern hair loss in the first half of 2027. It says VDPHL01, if approved, would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both men and women. A positive Study 306 result would support that claim, and a miss would weaken it.

The next quarterly report will show whether general and administrative spending holds near this quarter's level or keeps climbing as launch preparations continue.

More from OptimistFi

• MANE stock: research and coverage of Veradermics
• Stock research on every company OptimistFi covers

From OptimistFi Perps